Competitor Analysis: Dengue Virus Vaccines and Therapeutics

Date: July 2, 2012
Pages: 27
US$ 243.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CE8971A46D6EN

Download PDF Leaflet

Competitor Analysis: Dengue Virus Vaccines and Therapeutics
Dengue Virus Vaccines and Therapeutics

The present Competitive Intelligence Report about Dengue Virus Vaccines & Therapeutics provides a competitor evaluation in the field of investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of July 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

It is estimated that about 100 million cases of infection by Dengue virus occur each year and that nearly half the world’s population is at risk of Dengue virus infection. At present, no vaccines are available to prevent infection with mosquito-borne Dengue virus. There are four serotypes of Dengue virus, and neutralizing antibodies are serotype-specific with the risk of sequential infections. Although immunity against a specific serotype is life-long, but previous infection with one serotype is a risk factor for a more severe form of Dengue (Dengue hemorrhagic fever) upon subsequent infection with another serotype, thus emphasizing the need for a tetravalent vaccine against all four serotpyes of Dengue virus.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • Dengue Virus Vaccines
  • Dengue Virus Vaccines from NIH / NIAID
  • Dengue Virus Vaccines Licensed from NIH to Manufacturers in Developing Countries
  • Dengue Virus Therapeutics
  • CorporateDengue Virus Vaccines & Therapeutics R&D Pipeline
  • About La Merie

Skip to top

Competitor Analysis: HPV Vaccines US$ 180.00 May, 2010 · 18 pages
Competitor Analysis Influenza Vaccines US$ 718.00 May, 2011 · 123 pages
Competitor Analysis: Hepatitis Vaccines US$ 498.00 Jun, 2011 · 96 pages

Ask Your Question

Competitor Analysis: Dengue Virus Vaccines and Therapeutics
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: